Your browser doesn't support javascript.
loading
Neurobiological basis of reinforcement-based decision making in adults with ADHD treated with lisdexamfetamine dimesylate: Preliminary findings and implications for mechanisms influencing clinical improvement.
Newcorn, Jeffrey H; Ivanov, Iliyan; Krone, Beth; Li, Xiaobo; Duhoux, Stephanie; White, Stuart; Schulz, Kurt P; Bédard, Anne-Claude V; Pedraza, Juan; Adler, Lenard; Blair, Robert James.
Afiliación
  • Newcorn JH; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA. Electronic address: jeffrey.newcorn@mssm.edu.
  • Ivanov I; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
  • Krone B; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
  • Li X; Department of Biomedical Engineering, New Jersey Institute of Technology, Newark, NJ, USA.
  • Duhoux S; Formerly at Icahn School of Medicine at Mount Sinai, USA.
  • White S; Private Practice, Lincoln, NE, 68526, USA.
  • Schulz KP; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
  • Bédard AV; Ontario Institute for Studies in Education, University of Toronto, 252 Bloor Street West, Toronto, ON, M5S 1V6, USA.
  • Pedraza J; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
  • Adler L; New York University Crossman School of Medicine, New York, NY, 10016, USA.
  • Blair RJ; Center for Neurobehavioral Research, Boys Town National Research Hospital, Boys Town, NE, 68010, USA.
J Psychiatr Res ; 170: 19-26, 2024 Feb.
Article en En | MEDLINE | ID: mdl-38101205
ABSTRACT

BACKGROUND:

ADHD is often described as a disorder of altered reward sensitivity, yet few studies have examined the extent to which (i) treatments for ADHD impact reward-related mechanisms; and (ii) changes in the reward system are associated with clinical improvement. This study addresses these issues - examining the extent to which clinical improvement following lisdexamfetamine (LDX) treatment is associated with changes in brain reward system activation.

METHODS:

Twenty adults (M = 11, 55%, F = 9, 45%), ages 19-52 (M = 33.9, SD = 10.0) with ADHD participated in a randomized cross-over study with lisdexamfetamine (LDX) and placebo (PB). Changes in brain activation were assessed during functional magnetic resonance (fMRI) scans after receiving 3-5 weeks of treatment with LDX and 3-5 weeks of no drug/PB. fMRI contrasts were derived from the passive-avoidance (PA) learning task, which assessed reward-related learning using computational variables. We analyzed the following conditions the Choice-Phase, modulated by the expected value (EV; i.e., object-choose and object-reject), and the Feedback-Phase, modulated by the prediction error (PE; i.e., reward and punish). Clinical symptom severity was assessed via interview with the ADHD-Rating Scale (ADHD-RS-IV). To address the primary objective, we performed group-level mass-univariate regression analyses between LDX and PB of percent change of the ADHD-RS total scores and the four contrast images under the Choice- and Feedback-conditions. Significance was set at a whole-brain voxel-wise threshold of p < 0.05 with family-wise error (FWE) correction and an extent (cluster) threshold of 50 contiguous voxels.

RESULTS:

Improvement in ADHD symptoms with LDX was accompanied by significantly increased activation in a series of brain regions previously implicated in reinforcement processing in the choice and feedback conditions (e.g., left caudate and putamen, right orbitofrontal cortex, left middle frontal, superior frontal, and precentral gyri).

CONCLUSIONS:

These findings, while preliminary, are the first to show that ADHD symptom improvement with stimulant treatment is associated with increased responsiveness of brain systems engaged in reward processing. Results support the hypothesis that LDX treatment may restore balance to dysfunction (e.g., hypoactivation) within the brain reward circuitry in adults with ADHD. Trial RegistrationClinicaltrials.gov Identifier NCT01924429.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Trastorno por Déficit de Atención con Hiperactividad / Estimulantes del Sistema Nervioso Central Idioma: En Revista: J Psychiatr Res Año: 2024 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Trastorno por Déficit de Atención con Hiperactividad / Estimulantes del Sistema Nervioso Central Idioma: En Revista: J Psychiatr Res Año: 2024 Tipo del documento: Article